Q-omics provides the consensus-scored CA2 profile across patient tissues and cancer cell-line models. CA2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CA2 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, CA2 protein abundance shows 18,543 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, COAD, and PDAC as cancer lineages where CA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CA2 survival associations across molecular data types. CA2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CA2 RNA expression–survival associations across cancer types. High CA2 expression shows unfavorable associations in ACC, UVM, OV, LGG and BLCA, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CA2 RNA expression.
This table summarizes CA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CA2 shows lower tumor expression in COAD, KIRC, LUAD and LIHC and higher tumor expression in HNSC and UCEC. The COAD box plot shows higher CA2 RNA expression in normal versus tumor tissue (log2 FC = −5.410, t-test p < 0.001).
This table shows molecular features associated with CA2 in patient tissues and cancer cell lines. In patient samples, CA2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
